S C Gouw

Summary

Affiliation: University Medical Center Utrecht
Country: The Netherlands

Publications

  1. ncbi F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis
    Samantha C Gouw
    Department of Pediatrics, Wilhelmina Children s Hospital, University Medical Center Utrecht, Utrecht, The Netherlands
    Blood 119:2922-34. 2012
  2. ncbi Discordant antibody response in monozygotic twins with severe haemophilia A caused by intensive treatment
    S C Gouw
    Department of Pediatrics, Van Creveldkliniek, University Medical Center Utrecht, The Netherlands
    Haemophilia 15:712-7. 2009
  3. ncbi The multifactorial etiology of inhibitor development in hemophilia: genetics and environment
    Samantha C Gouw
    Department of Pediatrics, Wilhelmina Children s Hospital, Utrecht, The Netherlands
    Semin Thromb Hemost 35:723-34. 2009
  4. ncbi Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients
    S C Gouw
    Department of Paediatrics, Wilhelmina Children s Hospital, University Medical Center Utrecht, Utrecht, The Netherlands
    Haemophilia 17:275-81. 2011
  5. ncbi Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice
    P C ter Avest
    Department of Haematology Van Creveldkliniek, University Medical Center Utrecht, Utrecht, The Netherlands
    J Thromb Haemost 6:2048-54. 2008
  6. ncbi Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units
    P C ter Avest
    Department Clinical Chemistry and Haematology, Van Creveldkliniek, Utrecht, The Netherlands
    Haemophilia 16:71-9. 2010
  7. ncbi Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A
    S C Gouw
    Van Creveldkliniek, and Department of Pediatrics, University Medical Center Utrecht, Utrecht, The Netherlands
    J Thromb Haemost 5:1383-90. 2007

Collaborators

Detail Information

Publications7

  1. ncbi F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis
    Samantha C Gouw
    Department of Pediatrics, Wilhelmina Children s Hospital, University Medical Center Utrecht, Utrecht, The Netherlands
    Blood 119:2922-34. 2012
    ..6-1.5), and the risk in small deletions/insertions and missense mutations was lower (pooled OR = 0.5; 95% CI, 0.4-0.6 and OR = 0.3; 95% CI, 0.2-0.4, respectively). The relative risks for developing high titer inhibitors were similar...
  2. ncbi Discordant antibody response in monozygotic twins with severe haemophilia A caused by intensive treatment
    S C Gouw
    Department of Pediatrics, Van Creveldkliniek, University Medical Center Utrecht, The Netherlands
    Haemophilia 15:712-7. 2009
    ..This confirms that these environmental factors play an additional role in the development of inhibitors...
  3. ncbi The multifactorial etiology of inhibitor development in hemophilia: genetics and environment
    Samantha C Gouw
    Department of Pediatrics, Wilhelmina Children s Hospital, Utrecht, The Netherlands
    Semin Thromb Hemost 35:723-34. 2009
    ..This review summarizes the current knowledge on the potential risk factors of inhibitor development. At present, many uncertainties still remain that will require collaborative investigation...
  4. ncbi Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients
    S C Gouw
    Department of Paediatrics, Wilhelmina Children s Hospital, University Medical Center Utrecht, Utrecht, The Netherlands
    Haemophilia 17:275-81. 2011
    ..In conclusion, in agreement with earlier observations, the type and location of the F8 gene mutation were important determinants of inhibitor development in patients with severe haemophilia A...
  5. ncbi Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice
    P C ter Avest
    Department of Haematology Van Creveldkliniek, University Medical Center Utrecht, Utrecht, The Netherlands
    J Thromb Haemost 6:2048-54. 2008
    ..Management of bleeds and eradicating inhibitors is complicated, costly and not always successful...
  6. ncbi Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units
    P C ter Avest
    Department Clinical Chemistry and Haematology, Van Creveldkliniek, Utrecht, The Netherlands
    Haemophilia 16:71-9. 2010
    ..Patients with a maximum titre below 40 BU mL(-1) may also strongly benefit from the beneficial effects of low dose immune tolerance induction therapy...
  7. ncbi Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A
    S C Gouw
    Van Creveldkliniek, and Department of Pediatrics, University Medical Center Utrecht, Utrecht, The Netherlands
    J Thromb Haemost 5:1383-90. 2007
    ..The development of inhibitory antibodies against infused factor (F) VIII is a major complication of treatment of patients with severe hemophilia A...